These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 1751271)

  • 1. Clearance of atracurium and laudanosine in the urine and by continuous venovenous haemofiltration.
    Shearer ES; O'Sullivan EP; Hunter JM
    Br J Anaesth; 1991 Nov; 67(5):569-73. PubMed ID: 1751271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition of infusions of atracurium and its metabolite, laudanosine, in patients in renal and respiratory failure in an ITU.
    Parker CJ; Jones JE; Hunter JM
    Br J Anaesth; 1988 Nov; 61(5):531-40. PubMed ID: 3207525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atracurium infusions in patients with fulminant hepatic failure awaiting liver transplantation.
    Bion JF; Bowden MI; Chow B; Honisberger L; Weatherley BC
    Intensive Care Med; 1993; 19 Suppl 2():S94-8. PubMed ID: 8106686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma laudanosine levels in patients given atracurium during liver transplantation.
    Lawhead RG; Matsumi M; Peters KR; Landers DF; Becker GL; Earl RA
    Anesth Analg; 1993 Mar; 76(3):569-73. PubMed ID: 8452269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concentrations of atracurium and laudanosine in cerebrospinal fluid and plasma in three intensive care patients.
    Gwinnutt CL; Eddleston JM; Edwards D; Pollard BJ
    Br J Anaesth; 1990 Dec; 65(6):829-32. PubMed ID: 2265055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and dynamics of atracurium infusions after paediatric orthotopic liver transplantation.
    Chow B; Bowden MI; Ho E; Weatherley BC; Bion JF
    Br J Anaesth; 2000 Dec; 85(6):850-5. PubMed ID: 11732518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concentrations of atracurium and laudanosine in cerebrospinal fluid and plasma during intracranial surgery.
    Eddleston JM; Harper NJ; Pollard BJ; Edwards D; Gwinnutt CL
    Br J Anaesth; 1989 Nov; 63(5):525-30. PubMed ID: 2605068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics and atracurium and laudanosine concentrations during a fixed continuous infusion of atracurium in mechanically ventilated patients with acute respiratory distress syndrome.
    Lefrant JY; Farenc C; De la Coussaye JE; Muller L; Ripart J; Cuvillon P; Saissi G; Eledjam JJ
    Anaesth Intensive Care; 2002 Aug; 30(4):422-7. PubMed ID: 12180578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of 51W89: preliminary data.
    Hunter JM; Eastwood NB; Boyd AH; Parker CJ
    Acta Anaesthesiol Scand Suppl; 1995; 106():94. PubMed ID: 8533555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of atracurium and laudanosine in the elderly.
    Kent AP; Parker CJ; Hunter JM
    Br J Anaesth; 1989 Dec; 63(6):661-6. PubMed ID: 2611066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit.
    Boyd AH; Eastwood NB; Parker CJ; Hunter JM
    Br J Anaesth; 1996 Mar; 76(3):382-8. PubMed ID: 8785138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prolonged use of atracurium in a patient with tetanus.
    Peat SJ; Potter DR; Hunter JM
    Anaesthesia; 1988 Nov; 43(11):962-3. PubMed ID: 3213921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of atracurium and laudanosine in patients with hepatic cirrhosis.
    Parker CJ; Hunter JM
    Br J Anaesth; 1989 Feb; 62(2):177-83. PubMed ID: 2923767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laudanosine and atracurium concentrations in a patient receiving long-term atracurium infusion.
    Grigore AM; Brusco L; Kuroda M; Koorn R
    Crit Care Med; 1998 Jan; 26(1):180-3. PubMed ID: 9428564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure.
    Eastwood NB; Boyd AH; Parker CJ; Hunter JM
    Br J Anaesth; 1995 Oct; 75(4):431-5. PubMed ID: 7488483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of age on cis-atracurium besylate pharmacokinetics following a single 1 mg kg
    Aguilar A; Andaluz A; Moll X; Cristòfol C; García F
    Vet Anaesth Analg; 2019 Sep; 46(5):643-651. PubMed ID: 31155378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laudanosine (a metabolite of atracurium) increases the minimum alveolar concentration of halothane in rabbits.
    Shi WZ; Fahey MR; Fisher DM; Miller RD; Canfell C; Eger EI
    Anesthesiology; 1985 Dec; 63(6):584-8. PubMed ID: 2932981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience and plasma laudanosine concentrations during the infusion of atracurium in the intensive therapy unit.
    Yate PM; Flynn PJ; Arnold RW; Weatherly BC; Simmonds RJ; Dopson T
    Br J Anaesth; 1987 Feb; 59(2):211-7. PubMed ID: 3548792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic modelling of a parent drug and its metabolite. Atracurium and laudanosine.
    Nigrovic V; Banoub M
    Clin Pharmacokinet; 1992 May; 22(5):396-408. PubMed ID: 1505145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Creatinine and urea clearance during continuous veno-venous haemofiltration in critically ill patients.
    Brocklehurst IC; Thomas AN; Kishen R; Guy JM
    Anaesthesia; 1996 Jun; 51(6):551-3. PubMed ID: 8694207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.